ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

PHASE3CompletedINTERVENTIONAL
Enrollment

834

Participants

Timeline

Start Date

December 5, 2020

Primary Completion Date

September 3, 2021

Study Completion Date

October 8, 2021

Conditions
Dry Eye Disease
Interventions
DRUG

CyclASol topical ocular, eye drops

Cyclosporine A solution in vehicle

DRUG

Vehicle topical ocular, eye drops

Vehicle

Trial Locations (27)

16066

CYS-004 Investigational Site, Cranberry Township

24502

CYS-004 Investigational Site, Lynchburg

27603

CYS-004 Investigational Site, Raleigh

28150

CYS-004 Investigational Site, Shelby

33309

CYS-004 Investigational Site, Fort Lauderdale

37167

CYS-004 Investigational Site, Smyrna

38119

CYS-004 Investigational Site, Memphis

40206

CYS-004 Investigational site, Louisville

46240

CYS-004 Investigational Site, Indianapolis

46290

CYS-004 Investigational Site, Carmel

55364

CYS-004 Investigational Site, Medina

58103

CYS-004 Investigational Site, Fargo

60619

CYS-004 Investigational Site, Chicago

64111

CYS-004 Investigational Site, Kansas City

64154

CYS-004 Investigation Site, Kansas City

80907

CYS-004 Investigational Site, Colorado Springs

84041

CYS-004 Investigational Site, Layton

84403

CYS-004 Investigational site, Ogden

85032

CYS-004 Investigational Site, Phoenix

89052

CYS-004 Investigational Site, Henderson

90013

CYS-004 Investigational Site, Los Angeles

92663

CYS-004 Investigational Site, Newport Beach

92705

CYS-004 Investigational Site, Santa Ana

98119

CYS-004 Investigational Site, Seattle

01810

CYS-004 Investigational Site, Andover

02767

CYS-004 Investigational Site, Raynham

02886

CYS-004 Investigational Site, Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novaliq GmbH

INDUSTRY